中华灾害救援医学2025，Vol.12Issue(9)：1024-1028,5.DOI:10.13919/j.issn.2095-6274.ZHJY202506028
益肾养血汤治疗尿毒症血液透析患者肾性贫血的疗效观察
Observation on the Efficacy of Yishen Yangxue Decoction in Treating Renal Anemia in Uremic Patients Undergoing Hemodialysis
摘要
Abstract
Objective To investigate the effect of Yishen Yangxue Decoction on uremic patients with renal anemia undergoing hemodialysis.Methods Ninety～two uremic patients with renal anemia receiving hemodialysis in Jiangle General Hospital from January 2023 to August 2024 were enrolled and randomly divided into two groups using a random number table.The control group(n=46)received recombinant human erythropoietin(rhEPO)thera-py,while the observation group(n=46)received Yishen Yangxue Decoction in addition to the control treatment.The therapeutic efficacy,blood parameters,erythropoietin resistance index(ERI),average weekly rhEPO dosage,renal function,quality of life,and adverse reactions were compared between the two groups.Results The total effective rate was significantly higher in the observation group than in the control group(93.48%vs.78.26%,P<0.05).After treatment,the observation group showed significantly better results than the control group in terms of hemoglobin(Hb),hematocrit(HCT),serum ferritin(SF),transferrin saturation(TSAT),and quality of life scores.Meanwhile,the eryth-ropoietin resistance index,weekly rhEPO dosage,serum creatinine(Scr),and blood urea nitrogen(BUN)levels were significantly lower in the observation group than in the control group(P<0.05).The incidence of adverse reactions was lower in the observation group than in the control group(4.35%vs.17.39%,P<0.05).Conclusion Yishen Yangxue Decoction can improve the anemia status and renal function,reduce erythropoietin resistance and the re-quired rhEPO dosage in uremic hemodialysis patients with renal anemia,with a high safety profile.关键词
尿毒症/血液透析/肾性贫血Key words
Uremia/Hemodialysis/Renal anemia分类
医药卫生引用本文复制引用
魏晓维,徐华,刘由敏,钱燕坪,黄小妹..益肾养血汤治疗尿毒症血液透析患者肾性贫血的疗效观察[J].中华灾害救援医学,2025,12(9):1024-1028,5.基金项目
三明市科技计划项目(2022-S-35) （2022-S-35）
